Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $93000.0.

  • Utah Medical Products' Other Working Capital Changes rose 113333.33% to $93000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $34000.0, marking a year-over-year increase of 14250.0%. This contributed to the annual value of $3000.0 for FY2024, which is 65000.0% up from last year.
  • Latest data reveals that Utah Medical Products reported Other Working Capital Changes of $93000.0 as of Q3 2025, which was up 113333.33% from -$171000.0 recorded in Q2 2025.
  • In the past 5 years, Utah Medical Products' Other Working Capital Changes ranged from a high of $109000.0 in Q1 2021 and a low of -$171000.0 during Q2 2025
  • Moreover, its 5-year median value for Other Working Capital Changes was $21000.0 (2021), whereas its average is $4210.5.
  • As far as peak fluctuations go, Utah Medical Products' Other Working Capital Changes plummeted by 70000.0% in 2024, and later surged by 113333.33% in 2025.
  • Utah Medical Products' Other Working Capital Changes (Quarter) stood at $46000.0 in 2021, then grew by 28.26% to $59000.0 in 2022, then tumbled by 144.07% to -$26000.0 in 2023, then soared by 430.77% to $86000.0 in 2024, then rose by 8.14% to $93000.0 in 2025.
  • Its Other Working Capital Changes was $93000.0 in Q3 2025, compared to -$171000.0 in Q2 2025 and $26000.0 in Q1 2025.